Clinical Trial Update: Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

This is a Phase 1 clinical trial evaluating intravenous etentamig in combination with an oral CELMoD agent for adults with relapsed or refractory multiple myelo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Etentamig
• Oral CELMoD agent (unspecified)

Snippet

Sponsor: AbbVie | Conditions: Multiple Myeloma | Phase 1 | Status: RECRUITING